# US 11,077,121 B2 · Inhibition of thymine DNA glycosylase in the treatment of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,077,121 B2 - Document ID: US11077121B2 - Status: Granted - Kind: B2 - Application number: 15/084,680 - Filed: 2016-03-30 - Published: 2016-07-14 - Granted: 2021-08-03 - Earliest claimed: 2014-09-30 - Assignees: Institute For Cancer Research; Institut Curie; Institut de Genetique et de Biologie Moleculaire et Cellulaire - Applicants: Institute for Cancer Research; Institut Curie; Institut de Génétique et de Biologie Moléculaire et Cellulaire - Inventors: Alfonso Bellacosa; Rossella Tricarico; Tim Yen; Vikram Bhattacharjee; Pietro Mancuso; Lionel Larue; Irwin Davidson - Web page: https://patentgrep.com/patent/US11077121B2 ## CPC - A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha - A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin - A61K 31/277: having a ring, e.g. verapamil - A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin - A61K 31/404: Indoles, e.g. pindolol - A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines - A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375) - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61K 31/546: containing further heterocyclic rings, e.g. cephalothin - A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)} - A61K 33/24: Heavy metals; Compounds thereof - A61K 33/243: Platinum; Compounds thereof - A61P 35/00: Antineoplastic agents - C12N 2740/15043: viral genome or elements thereof as genetic vector - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells. ## Claims ### Claim 1 A method of treating a patient having melanoma, prostate cancer, colon cancer, or glioblastoma, comprising administering to the blood of the patient in need thereof an amount of aurothioglucose effective to inhibit TDG in cells of the melanoma, prostate cancer, colon cancer, or glioblastoma. ### Claim 2 (depends on 1) The method according to claim 1, further comprising administering temozolomide to the patient. ### Claim 3 (depends on 1) The method according to claim 1, further comprising administering cisplatin to the patient. ### Claim 4 (depends on 1) The method according to claim 1, further comprising administering vincristine to the patient. ### Claim 5 (depends on 1) The method according to claim 1, further comprising administering a RAD51 inhibitor to the patient. ### Claim 6 A method of treating a patient having prostate cancer comprising administering to the blood of the patient in need thereof an inhibitor of TDG in the amount effective to inhibit TDG in cells of prostate cancer, wherein the TDG inhibitor comprises aurothioglucose. ### Claim 7 (depends on 6) The method according to claim 6, further comprising administering temozolomide to the patient. ### Claim 8 (depends on 6) The method according to claim 6, further comprising administering cisplatin to the patient. ### Claim 9 (depends on 6) The method according to claim 6, further comprising administering vincristine to the patient. ### Claim 10 (depends on 6) The method according to claim 6, further comprising administering a RAD51 inhibitor to the patient. ### Claim 11 (depends on 1) The method according to claim 1, wherein the patient has melanoma. ### Claim 12 (depends on 1) The method according to claim 1, wherein the patient has glioblastoma. ### Claim 13 A method of treating a patient having colon cancer comprising administering to the blood of the patient in need thereof an inhibitor of TDG in the amount effective to inhibit TDG in cells of the colon cancer, wherein the TDG inhibitor comprises aurothioglucose. ### Claim 14 (depends on 13) The method according to claim 13, further comprising administering temozolomide to the patient. ### Claim 15 (depends on 13) The method according to claim 13, further comprising administering cisplatin to the patient. ### Claim 16 (depends on 13) The method according to claim 13, further comprising administering vincristine to the patient. ### Claim 17 (depends on 13) The method according to claim 13, further comprising administering a RAD51 inhibitor to the patient.